Bixiye
QP29-23 Blue Cross Preferred Genetic Laboratory Program
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 841 - 850 ee natiijooyinka 3606
Bixiye
QP30-23 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective May 1, 2023
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP31-23 Commercial Pharmacy Benefit Exclusion for Fluticasone-Salmeterol
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP32-23 Review and Update NPI Information
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP33-23 Provider Survey: Training & Development Focusing on Equity in Health Care
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP34-23 Update for New to Market Medical Drugs: Tofersen
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP35-23 Notice of Correction to Ambulance Mileage Reimbursement
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Faa'iidooyinka & Caymiska
BlueRide Parent or Guardian Ride Consent Form
Bixiye
P17-23 Inflation Reduction Act (IRA): Part B Rebatable Drugs and Part B Insulin Cap
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 03, 2023
Bixiye
P18-23 Updated Minnesota Health Care Programs (MHCP) and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 03, 2023